ライフサイエンスコーパス: alive

1 others of newborns who died after being born alive.

2 ne patient progressed, and all patients were alive.

3 rd the ISS for 35 days and returned to Earth alive.

4 e 160 patients finally included, 87 remained alive.

5 IV) were seen in 9 of the 14 patients still alive.

6 35-day mission, mice were returned to Earth alive.

7 atively compatible with, since the mother is alive.

8 ho were hospitalized with AMI and discharged alive.

9 pleted for 299 (99%), of whom 169 (57%) were alive.

10 n to a metabolically active state and remain alive.

11 nlytic toxins leave large patches of E. coli alive.

12 78) were dichotomized as died or discharged alive.

13 n "opt-out" policy, or donate a kidney while alive.

14 e MIS3 climatic optimum when the mammoth was alive.

15 of the analysis, 5 patients (23%) were still alive.

16 At 10 years, 63.9% of patients were alive.

17 splant (43 of 52; age range, 3-69 years) are alive.

18 of the patients who received emapalumab were alive.

19 was found in OPTN + all (OPTN + all [Assumed Alive]).

20 .94), and decreased probability of discharge alive (0.61, 0.45-0.83).

21 st half of women with stage IV breast cancer alive 1 year after diagnosis, and is increasingly occurr

22 5) for the two predicted groups (dead versus alive 1 year after ECG) over a 25-year follow-up period.

23 with scores 7 or more and less than 11 were alive 1 year later.

24 At last follow-up, 69 patients were alive, 100 underwent LT and 171 died without LT.

25 ommon cancers who were 18 years or older and alive 12 months after diagnosis and controls without his

26 Those with intact primary tumors who were alive 12 months after diagnosis were categorized by trea

27 y was accomplished in 2 patients that remain alive 13 and 62 months, respectively, following metastas

28 mortality (died 21.9 [13.9, 30.3] ng/mL vs. alive 15.2 [9.8, 23.0] ng/mL; P < 0.001), higher Acute K

29 and 62% male), 381 (62%) had been discharged alive, 178 (29%) died and 55 (9%) remained hospitalized

30 complications and eight patients (88%) were alive 24 hours after intubation.

31 nts and 21 (87%) TBP>30% patients were still alive; 27 (32%) and 11 (46%), respectively, continued to

32 (n = 1151, 20.2%), 38 (3.3%) were discharged alive, 282 (24.5%) died, and 831 (72.2%) remained in hos

33 n with SAM at 6 months of age (227/230) were alive 3 months later, 40% (92/230) were still SAM, and 1

34 h MI, discharged on beta-blocker therapy and alive 3 years later without a recurrent MI to evaluate b

35 19 (95%) of 20 patients alive 30 days after implantation were NYHA class I or II

36 Among 1751 LTFU patients traced and found alive, 31% of patients starting ART between July 1 2013

37 umab before and after primary surgery remain alive 33 and 28 months later.

38 %) were successfully weaned off and 42% were alive 6 months post-ICU admission.

39 ventilator, 16 (30.2%) have been discharged alive, 7 (13.2%) have been decannulated, and 6 (11.3%) d

40 2,098 unselected patients, 73.1% were still alive after 10 years.

41 Nineteen (86%) patients were alive after a median post-LT follow-up of 48 months, whe

42 Sixteen patients are alive after an average of 30 days post-LT (range 3-46).

43 ygen-free days were defined as any day while alive after diagnosis of RSV infection during which </=2

44 erilised blood-fed mosquitoes which remained alive after exposure to the net.

45 ipheral arterial disease who were discharged alive after peripheral arterial revascularization, the 3

46 randomly assigned to groups) who were still alive after the index admission, at a mean 86 months (+/

47 mtDNA CN was measured in the ALIVE (AIDS Linked to the Intravenous Experience) cohort

48 ), of the entering 43 patients, 9 (21%) were alive and 34 (79%) had died of systemic metastasis.

49 ptic shock, 346 of 389 subjects (88.9%) were alive and 43 of 389 had died (11.1%); 203 of 389 (52.2%)

50 At 10 years, 104 (17%) patients were alive and 92 (88%) answered the HRQOL questionnaires.

51 The headnecks were immotile but alive and capable of producing offspring by intracytopla

52 .3 years; 66.8% women), 195 (62.9%) remained alive and completed the trial.

53 ficance of these neurons to keep their axons alive and connected.

54 Patients remaining alive and consenting to participate had a follow-up visi

55 nts in each group, at least 24 patients were alive and disease free at 2 years).

56 essment was undertaken for patients who were alive and disease free, which included measurement of le

57 At last follow-up, 41 patients (80%) were alive and disease-free, eight (16%) had died of progress

58 The patient is still alive and doing well after the LDLT.

59 pportunity to self-report (ie, patients were alive and enrolled in a treatment trial at the time of t

60 Among 75 nivolumab-treated patients alive and evaluable at the 5-year analysis, 83% had not

61 toff on August 7, 2017, all 15 patients were alive and event-free at 20 months of age, as compared wi

62 were enriched at each time point in subjects alive and extubated within 28 days after ARDS onset (ali

63 ase the number of ventilator-free days (days alive and free from mechanical ventilation).

64 s during the first 28 days, defined as being alive and free from mechanical ventilation.

65 ays all-cause mortality rate; number of days alive and free of advanced organ support at day 28; and

66 2%], respectively; p = 0.56), number of days alive and free of advanced organ support, adverse events

67 lent heart failure had a predicted mean time alive and free of AF of 7.9 years.

68 y of heart failure had a predicted mean time alive and free of AF of 9.9 years, whereas a 70-year-old

69 sk of AF corresponded to predicted mean time alive and free of AF of 9.9, 9.6, and 8.8 years, respect

70 Patients experienced more days alive and free of delirium and coma with both total bund

71 4.8%) in the axial-flow pump group, remained alive and free of disabling stroke or reoperation to rep

72 end point was organ support-free days (days alive and free of ICU-based respiratory or cardiovascula

73 n reported; 15 of the 17 patients (88%) were alive and free of major functional disability, with mini

74 in the number of ventilator-free days (days alive and free of mechanical ventilation) over 28 days.

75 sessment scores from baseline to day 7, days alive and free of mechanical ventilation, days alive and

76 vival, defined as the proportion of patients alive and free of progression at 6 months, assessed in p

77 etween gentamicin use and the number of days alive and free of renal failure, shock, and death, all o

78 ive and free of mechanical ventilation, days alive and free of vasopressor, renal replacement therapy

79 38 study participants were included who were alive and had available NT-proBNP results 90 days after

80 act 95% confidence interval, 90 to 100) were alive and had excellent graft function and an undetectab

81 A total of 479 patients with ALS were alive and had not undergone tracheostomy at the prevalen

82 o received nusinersen were more likely to be alive and have improvements in motor function than those

83 Newborns were alive and healthy.

84 63 (75%): 412 (19%) had died, 836 (39%) were alive and in care at their original clinic, 457 (21%) ha

85 We included all adults (aged >=18 years) alive and in follow-up on Feb 1, 2020, and with at least

86 All others were alive and in remission at last follow-up (median, 14.7 m

87 ong 858 enrolled patients, 646 patients were alive and in the hospital on day 4 and included in the m

88 penem resistance on probability of discharge alive and in-hospital death, and multistate modelling fo

89 ioreactor design which maintains human cells alive and metabolically active for up to 72 h, and a sem

90 mortality (11% vs 1%, P = .004), fewer days alive and nonhospitalized (73 vs 81, P = .039), and decr

91 rtality, total hospitalizations for HF, days alive and not hospitalized for cardiovascular reasons, t

92 Among 36 participants alive and not in care at 24 months with ascertained stat

93 ho did not relapse, the probability of being alive and not needing additional melanoma therapy at 3 y

94 Of 8,010 enrolled patients, 4,433 were alive and not withdrawn at an LTFU participating center,

95 hese 4 groups, 1-year probabilities of being alive and off all systemic immunosuppression were 61%, 5

96 transferred to a new clinic, 255 (12%) were alive and out of care, and 203 (9%) were alive but we we

97 ospitalizations and death and increased days alive and out of hospital (DAOH) and percent DAOH in ODY

98 size, and the duration of time subjects was alive and out of hospital (P=0.05).

99 the primary end point of the number of days alive and out of hospital at 30 days (median [interquart

100 The primary end point was the number of days alive and out of hospital at 30 days.

101 30- and 90-day readmission or death and days alive and out of hospital within 12 months of discharge.

102 ere was no between-group difference for days alive and out of hospital within 14 days after recruitme

103 The primary outcome was the number of days alive and out of hospital within 14 days after recruitme

104 ed with standard care for the number of days alive and out of hospital, and reduced the duration of s

105 zation 90 days pre-LT and the number of days alive and out of the hospital (DAOH) 1 year post-LT.

106 significant difference in the number of days alive and out of the hospital at 30 days.

107 rence was observed in the proportion of days alive and out of the hospital to 1 year (rate ratio: 1.0

108 Death, stroke, and days alive and out of the hospital to 1 year were compared, a

109 The proportion of patients alive and progression free at 24 weeks did not differ be

110 n 1992 and 2015 in Ontario, Canada, who were alive and relapse free 30 days after treatment completio

111 Patient 1 is alive and remains disease-free 36 months after completio

112 duals born in Denmark in 1967-2000, who were alive and residing in Denmark on their 15th birthday, an

113 dividuals aged 35 years or younger, who were alive and residing in the country on their 15th birthday

114 Home time was defined as the number of days alive and spent outside of a hospital, skilled nursing f

115 All participants were alive and transplant-free at one year, with only one cli

116 high doses of opioids and expected to remain alive and ventilated for an additional 48 hours and who

117 Within the four trials (n = 2,410 patients), Alive and Ventilator Free and ventilator-free days score

118 proaches to interpretation of differences in Alive and Ventilator Free are also presented.

119 Alive and Ventilator Free compares each patient with eve

120 Alive and Ventilator Free is less prone to favor a treat

121 Alive and Ventilator Free less often found in favor of t

122 a novel hierarchical composite endpoint, the Alive and Ventilator Free score.

123 ator-free days score had similar power, with Alive and Ventilator Free slightly more powerful when a

124 We evaluated power of Alive and Ventilator Free versus ventilator-free days sc

125 A hierarchical composite endpoint, Alive and Ventilator Free, preserves statistical power w

126 The primary outcome was number of days alive and was assessed as delirium-free and coma-free in

127 ped and the patient died; other children are alive and well (mean follow-up, 65 months).

128 All patients are alive and well with no new vascular events and resolutio

129 Nine were alive and well, 1 was alive with metastases, and 6 had d

130 All patients remain alive and well.

131 censoring, Dec 1, 2019, if individuals were alive), and PSP phenotype (with reference to the 2017 Mo

132 metastases or secondary neoplasms, 81% were alive, and 14% were lost to follow-up.

133 1%) of these women had died, 1118 (52%) were alive, and 159 (7%) were censored early.

134 ely 34 months), 25/30 (83.33%) patients were alive, and 21/30 (70.00%) remained free of disease.

135 nse was not yet reached; all responders were alive, and eight had responses lasting 12 months or long

136 e Critically Ill category, time to discharge alive, and protein and energy intake, whereas in the 4-d

137 o-first event, unmatched win-ratio, and days-alive-and-out-of-hospital composites are derived for com

138 alized days/1,000 d for those who were still alive; and 57 hospitalized days/1,000 d and 412 hospital

139 the New York City HIV surveillance registry alive as of 1 January 2013 and diagnosed with HIV as of

140 All patients remained alive as of Aug 4, 2019, and the median follow-up durati

141 following care categories: (1) diagnosed and alive as of June 1, 2016; (2) retained in care; (3) appr

142 complete response (20%), 88% (37 of 42) were alive as of the 5-year analysis.

143 vere secondary mitral regurgitation who were alive at 1 month, those randomized to TMVr were more lik

144 assist device (LVAD) were more likely to be alive at 1 year on original therapy with >/=75-m improve

145 Of 25 (66%) patients alive at 1 year, 15 reported return to preoperative pulm

146 rate or severe LVH treated with TAVR who are alive at 1 year, greater LVMi regression at 1 year is as

147 I, II, and S3 trials or registries and were alive at 1 year, we included patients with baseline mode

148 only 50% of renal transplant recipients are alive at 10 years due to the toxicities of immunosuppres

149 6.9-41.0) versus 25% (18.4-31.6) of patients alive at 18 months.

150 Twenty percent of patients were alive at 2 years.

151 Eleven patients (48%) were alive at 24 months.

152 complication, and 67(35%) of those who were alive at 28 days were parenteral nutrition free.

153 onfidence interval, 0.39-0.78) patients were alive at 3 months after enrollment.

154 cancer, the percentage of patients who were alive at 3 years was significantly higher among those wh

155 ived daptomycin monotherapy, 67 (58.8%) were alive at 30 days.

156 mab and 14% with dacarbazine; among patients alive at 5 years, ORR was 81% and 39%, respectively.

157 available for 523 of 914 participants (57%) alive at 5 years.

158 In patients who were alive at 6 months (median follow-up, 42 months; interqua

159 October 1, 2013, and February 10, 2015, and alive at 6 months of age were followed up at 9, 12, and

160 At last evaluation, 277 patients (91%) are alive at 62+/-13 years of age, including 89% in New York

161 ntion group, 60 of 337 patients (17.8%) were alive at 90 days vs 52 of 334 (15.6%) in the control gro

162 All patients are alive at a median follow-up of 1.6 (interquartile range,

163 rty-four percent of patients were discharged alive at a median time of 30 days (interquartile range,

164 Of 1037 original participants, 1007 were alive at age 38 years, of whom 565 (56%) had been lead t

165 Of 1037 original participants, 997 were alive at age 45 years, of whom 564 (57%) had received le

166 patients overall; all responders were still alive at data cutoff.

167 ICU mortality, and ventilator-free days and alive at day 28 were retrospectively analyzed using regr

168 ion clinical composite endpoint, defined as: alive at day 28, <=3 debridements, no amputation beyond

169 monia, with 0% of mice infected with CSE-PSA alive at day 6, while 28% of controls survived.

170 December 31, 2016, with no history of IE and alive at discharge were identified using data from Danis

171 uration of follow-up: 495 +/- 3.5 days) were alive at discharge with known antithrombotic treatment a

172 low-up of 129 non-operated patients with PVE alive at discharge.

173 llow-up of 129 nonoperated patients with PVE alive at discharge.

174 was higher in patients who died versus those alive at end of study (185+/-668 versus 17+/-482 mm Hg.d

175 tastases and 1 of unrelated causes; 2 remain alive at last review.

176 Of those patients alive at LT discharge, 24.7% spent >/=30 days hospitaliz

177 All patients are alive at median follow-up 7.4 years (range, 2.7 to 10 ye

178 15 031 patients arrived alive at military MTF after TBI.

179 is no cure, thousands of individuals who are alive at present will succumb to the disease.

180 viduals born during the period 1967-2008 and alive at record linkage (2012).

181 had uneventful postoperative courses and are alive at the 1-year time point with excellent performanc

182 Of 25 evaluable participants, 10 were alive at the completion of follow-up, while 5 were disea

183 mild or no symptoms occurred in all patients alive at the end of follow-up.

184 All patients were alive at the end of the follow-up.

185 Mortality outcomes for the 1,855 patients alive at the end of the SCD-HeFT trial were collected be

186 90.5% completed the trial (93.5% among those alive at the end of the trial).

187 bryonal rhabdomyosarcoma), all patients were alive at the time of analysis.

188 All 5 were alive at the time of last follow-up with good graft func

189 Ninety-three percent were alive at the time of review.

190 ch to assess the mortality of women who were alive at their final WISE contact date.

191 patients were enrolled; 84.1% (658/782) were alive-at-home at 1 year.

192 nt of patients discharged to a facility were alive-at-home at 1 year.

193 One-year alive-at-home status and 1-year PRO are meaningful, pati

194 that underwent randomization, 1566 were born alive before 30 weeks of gestation; of these, 782 were a

195 one coronary angiography and were discharged alive between 2009 to 2017 without a prior ICD, were fol

196 nal Registry with all renal transplanted men alive between January 1, 1995 and December 31, 2015 were

197 re after 180 days (33%; n = 2,976) and being alive but not in care in the Western Cape (25%; n = 2,25

198 hospital admission, other hospital contact, alive but not in care, no information) after disengageme

199 ere alive and out of care, and 203 (9%) were alive but we were unable to determine care status.

200 of patients are discharged from the hospital alive, but the median time-to-discharge is 1 month.

201 well as the subset of LTFU patients who were alive, contacted in person by the tracer, and out of car

202 ator of death and were more fearful of being alive during organ donation.

203 Serially sampled alive/extubated(Day28) subjects were characterized by an

204 ted from dead/intubated(Day28) compared with alive/extubated(Day28) subjects.

205 icantly enriched in AMs isolated on Day 1 in alive/extubated(Day28) versus dead/intubated(Day28) subj

206 d extubated within 28 days after ARDS onset (alive/extubated(Day28)) versus those dead or persistentl

207 ion was derived from all patients discharged alive for ADHF in the Get With The Guidelines-HF registr

208 e may permit xylem vessel elements to remain alive for later exploitation by the parasite.

209 l bowel remained continuously weaned off and alive for one year.

210 the other half attributed one point per day alive free of organ support up to a predefined time poin

211 (from 1=discharged to 6=death) or discharged alive from hospital, whichever came first.

212 stics, the hazard ratio for being discharged alive from ICU in the control group was 1.17 (95% CI, 0.

213 Consecutive adult patients discharged alive from ICU to hospital wards between September 2009

214 or older at time of study, 3010 (54.5%) were alive, had enrolled, and had had prospective clinical as

215 erences between groups in time to extubation alive (hazard ratio [HR], 1.16 for short- vs long-course

216 % CI, .55-1.22]), time to hospital discharge alive (HR, 1.07 [95% CI, .91-1.26]), or hospital death (

217 Twin Registry born between 1926 and 1996 and alive in 2006.

218 Individuals who were alive in 2009 were included in the present study.

219 For children alive in 2015 (n = 13,729,000), this would avert 240,000

220 Globally, of the 7.33 billion people alive in 2015, an estimated 36.0 million (80% uncertaint

221 lower mortality and faster time to discharge alive in high-risk, longer stay patients but not signifi

222 t at 6 wk, 7 of 7 and 3 of 7 mice were still alive in the (19)F/(177)Lu-rhPSMA-7.3 and (177)Lu-PSMA I

223 They are still alive in their 30s and 40s and show predominant ataxia a

224 Almost 2 years later the patient is alive, in good general condition, although slight progre

225 conditions in which the snake was kept when alive, leading to dehydration.

226 metastatic or inoperable disease were still alive more than 12 y after the beginning of radionuclide

227 67.2%) in the delayed angiography group were alive (odds ratio, 0.89; 95% confidence interval [CI], 0

228 ng hospital (n=145 592), 46% were discharged alive, of which 49% were discharged home.

229 nd July 15, 2008, 505 995 of whom were still alive on Jan 1, 2009, and contributed to the present stu

230 ive species reaching the Antarctic continent alive on kelp rafts.

231 Participants alive on or after April 1, 2003, in the Veterans Aging C

232 Twenty nine patients are still alive on support (support ranging from 1213 to 3396 days

233 Participants were all Swedish residents alive or born between 1968 and 2013 (n = 4,255,196 uniqu

234 iscordance in the hospital discharge status (alive or dead) for only 0.47% of all linked records (kap

235 dmissions in 180 days and the number of days alive out of the hospital in 180 days.

236 In addition, SIPAT was associated with days alive outside of the hospital ( P=0.016).

237 2-1.37; P=0.99) or the median number of days alive outside of the hospital (178 versus 179 days for N

238 hazard ratio, 3.20; P = .006) and fewer days alive outside the hospital within 90 days (median [IQR],

239 mated the predicted mean time free of AF and alive over a time horizon of 10 years.

240 We counted the number of locusts alive over the course of 2 weeks and showed that fewer f

241 e transmission rates caused by contacts with alive patients and sexual activities with convalescent p

242 Median follow-up for alive patients was 7.9 months.

243 Among patients admitted alive, PCI was the most important mortality-reduction pr

244 Among patients found to be alive, personally contacted, and out of care, tracing in

245 The presence of alive roots in the litterbags decreased root litter C re

246 Responders were defined as alive, showing improvement in 2 or more of the 4 CABP sy

247 ID, the AIDS Link to Intravenous Experience (ALIVE) Study, analyzing HIV-positive participants who ha

248 e majority of these cells are expected to be alive, they are speculated to be persisting in a state o

249 In Burkina Faso, the Alive & Thrive initiative combined interpersonal communi

250 his study was to determine the effect of the Alive & Thrive initiative on exclusive breastfeeding in

251 All patients >20 years old who arrived alive to hospital after OHCA between April 1, 2007, and

252 ned conceptions to the contrary, taxonomy is alive today although constantly struggling for survival

253 H; Equus ferus przewalskii), the only horses alive today not successfully domesticated by humans, and

254 rette and that about 5.6 million adolescents alive today will die prematurely from a smoking-related

255 have undergone the Fontan procedure and are alive today, most of whom are <25 years of age.

256 8%) 8 patients survived to discharge and are alive today.

257 Here, we utilized alive tumor tissues in ex-vivo platform termed CANscript

258 n were compared to those who were discharged alive using machine learning algorithms.

259 These players come alive via their own words, as complex individuals, both

260 dian follow-up for patients last known to be alive was 35.2 months (IQR 22.9-39.9).

261 Median follow-up time for patients still alive was 8.4 years.

262 ation and/or amputation) and were discharged alive were identified in the 2013 to 2014 Nationwide Rea

263 report, 83% (5/6) of the patients are still alive with 1 death on ECMO, attributed to hemorrhagic st

264 on the outcome of fetuses and children born alive with a CHD.

265 tients (10.2%) in the hypothermia group were alive with a CPC score of 1 or 2, as compared with 17 of

266 At 24 months, 36.4% of TMVr patients were alive with a moderately large (>=10-point) improvement v

267 Alive with acceptable patient-reported outcomes is achie

268 ts >=80 years (n=14 005) who were discharged alive with aspirin combined with either clopidogrel (60.

269 nty-six (42%) of 62 patients were discharged alive with Cerebral Performance Category 1 or 2 versus 2

270 atients had lower platelet counts than those alive with CFLD (143 versus 258 U/L, P = 0.004) or those

271 Three of them died, and 1 is alive with hepatic metastasis.

272 rtion of patients with an excellent outcome (alive with KCCQ-OS >=75 and no significant decline from

273 Twenty-three patients (50%) are currently alive with median follow-up of 4.0-years (11 months-11.8

274 Nine were alive and well, 1 was alive with metastases, and 6 had died of metastatic dise

275 Of all persons born preterm, 54.6% were alive with no AYA HOPE comorbidities at the end of follo

276 All patients are alive with survival times from HCC diagnosis ranging fro

277 At the end of follow-up, 70 patients were alive, with 67 patients being free of disease.

278 atients progressed and 21 of 31 (68%) remain alive, with 8 (26%) deaths related to new-onset graft-ve

279 She is alive, with a stable disease restricted to the stomach,

280 ss likely to be discharged from the hospital alive within 28 days than those in the usual-care group

281 Three patients with stable disease are alive without any evidence of progression during 24 to 2

282 The mean number of days alive without delirium and without coma at day 14 did no

283 r filtration rate and the number of patients alive without dialysis) 1 y after transplant.

284 he estimated percentage of patients who were alive without disease progression at 30 months was 70.6%

285 st follow-up, 174 (94%) of 185 patients were alive without disease, and four patients with disease.

286 The percentage of patients who were alive without distant metastasis was 65% (95% CI, 61 to

287 5 to 5.06; P = .036), with 89.5% of patients alive without distant recurrence at 3 years in the nonad

288 Secondary end points were patients alive without events (AWE)-namely, radiographic progress

289 nt was event-free survival, defined as being alive without graft failure; risk factors were studied u

290 Super-responders were defined as those alive without HF hospitalization and with >=20-point imp

291 Responders were defined as those alive without HF hospitalization and with a 5 to <20-poi

292 turned to care (some "silently") or remained alive without hospitalization, suggesting that many who

293 5 years, the percentage of patients who were alive without relapse was 52% (95% confidence interval [

294 e stratified the cohort by patients who were alive without retransplant at 1 year (n=664) and patient

295 ted 37% of candidates listed in 2012-15 were alive without transplant as compared to 22% in 2001-04.

296 54.3% of patients intubated preimplant were alive without transplant, 20.1% had been transplanted, a

297 onths), with 64% of patients estimated to be alive without TV reintervention or a valve-related event

298 Overall, 4 of 6 patients remain alive, without disease relapse and with long-term renal

299 post-HSCT, respectively, both patients were alive, without evidence of graft-versus-host disease, wi

300 Up to 70 000 patients may be alive worldwide today with Fontan circulation, and this